tradingkey.logo
tradingkey.logo
Search

Avidity Biosciences Inc

RNA
Add to Watchlist
13.650USD
+0.350+2.63%
Close 07/02, 13:00ETQuotes delayed by 15 min
2.00BMarket Cap
LossP/E TTM

TradingKey Stock Score of Avidity Biosciences Inc

Currency: USD Updated: 2026-07-02

Key Insights

Avidity Biosciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 55 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.00.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Avidity Biosciences Inc's Score

Industry at a Glance

Industry Ranking
55 / 157
Overall Ranking
130 / 4565
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Avidity Biosciences Inc Highlights

StrengthsRisks
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 94.75% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 18.62M.
Overvalued
The company’s latest PE is -4.72, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.97M shares, increasing 42.34% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 22.58K shares of this stock.

Analyst Rating

Based on 3 analysts
Buy
Current Rating
25.000
Target Price
+87.97%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Avidity Biosciences Inc?

The TradingKey Stock Score provides a comprehensive assessment of Avidity Biosciences Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Avidity Biosciences Inc’s performance and outlook.

How do we generate the financial health score of Avidity Biosciences Inc?

To generate the financial health score of Avidity Biosciences Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Avidity Biosciences Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Avidity Biosciences Inc.

How do we generate the company valuation score of Avidity Biosciences Inc?

To generate the company valuation score of Avidity Biosciences Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Avidity Biosciences Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Avidity Biosciences Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Avidity Biosciences Inc.

How do we generate the earnings forecast score of Avidity Biosciences Inc?

To calculate the earnings forecast score of Avidity Biosciences Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Avidity Biosciences Inc’s future.

How do we generate the price momentum score of Avidity Biosciences Inc?

When generating the price momentum score for Avidity Biosciences Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Avidity Biosciences Inc’s prices. A higher score indicates a more stable short-term price trend for Avidity Biosciences Inc.

How do we generate the institutional confidence score of Avidity Biosciences Inc?

To generate the institutional confidence score of Avidity Biosciences Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Avidity Biosciences Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Avidity Biosciences Inc.

How do we generate the risk management score of Avidity Biosciences Inc?

To assess the risk management score of Avidity Biosciences Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Avidity Biosciences Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Avidity Biosciences Inc.